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ABSTRACT 
Theophylline has been used in the treatment of airway dis-
eases, for more than 50 years with benefit thought to be 
derived from its ability to elicit bronchodilatation. Recent evi-
dence has, however, suggested that theophylline possesses 
anti-inflammatory activity. The molecular mechanism of 
action remains unclear, although inhibition of the phospho-
diesterase (PDE) enzyme, an enzyme which catalyzes the 
breakdown of cAMP and cGMP, has been proposed. 
Theophylline is a relatively weak inhibitor of PDE although
there is evidence to suggest that PDE activity is elevated in 
leukocytes from patients with atopic disease. Thus, an altered 
responsiveness to PDE inhibitors may partly explain the
mechanism of action of theophylline. The PDE enzyme exists 
as the least of seven different isoenzyme forms which can be 
characterized on the basis of a number of criteria including 
substrate specificity, sensitivity to selective inhibitors and the
effect of allosteric modulators. The type IV isoenzyme is the 
predominant isoenzyme in inflammatory cells although it 
exists together with the type III isoenzyme in T-lymphocytes. 
There is considerable evidence from in vitro and in viva stud-
ies suggesting that selective PDE IV inhibitors have anti-
inflammatory activity. The following article reviews these 
studies, together with clinical studies demonstrating that 
theophylline has anti-inflammatory activity.
INTRODUCTION 
Theophylline and related xanthines have been used in the treat-
ment of diseases of the airways for over 50 years and remain
widely prescribed drugs world-wide for the treatment of 
bronchial asthma.1-3 The therapeutic effectiveness of this class
of drugs was traditionally thought to be derived from their ability 
to produce bronchodilatation. However, it is now becoming
increasingly apparent that theophylline, in particular, has both 
immunomodulatory and anti-inflammatory activity. Although
theophylline has been used extensively in the treatment of 
asthma, its molecular mechanism(s) is not clear. Several puta-
tive mechanisms of action have been suggested to explain the 
therapeutic effectiveness of theophylline and related xanthines. 
One mechanism that has been proposed is that theophylline,
through non-selective phosphodiesterase (PDE) inhibition, 
raises intracellular cyclic 3',5'-adenosine monophosphate
(cAMP) and cyclic 3',5'-guanosine monophosphate (cGMP) 
levels resulting in relaxation of airway smooth muscle and inhi-
bition of inflammatory cell activation. Theophylline is a relatively
weak inhibitor of PDE, although there is evidence to suggest that 
PDE activity is elevated in leukocytes from patients with atopic 
disease (atopic dermatitis, asthma, allergic rhinitis),4 and thus 
an altered responsiveness to PDE inhibitors may partly explain 
the mechanism of action of theophylline.
 Seven gene families of the PDE enzyme have so far been 
defined, each of which can be distinguished by a variety of cri-
teria including their substrate specificity, sensitivity to selective 
inhibitors and the effect of allosteric modulators.5 The type IV
isoenzyme appears to be the main isoenzyme of PDE inflamma-
tory cells, although it exists together with the type III isoenzyme in 
T cells.6 It is becoming increasingly apparent that theophylline
possesses anti-inflammatory and immunomodulatory actions7-9 
that may well contribute to the clinical efficacy of this drug in the 
treatment of asthma.
EFFECTS OF THEOPHYLLINE AND SELECTIVE 
PDE ISOENZYME INHIBITORS ON CELLS INVOLVED 
I N ASTHMA
The PDE isoenzymes have now been characterized in many 
inflammatory cells and a variety of studies have examined the 
potential anti-inflammatory effect of theophylline and selective
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PDE isoenzyme inhibitors on these cells. These include mast 
cells, basophils, lymphocytes, natural killer cells, eosinophils, 
neutrophils and macrophages.
IN VITRO STUDIES
Effects on mast cells
Human lung mast cells release a variety of mediators including 
histamine, leukotriene C4 (LTC4) and prostaglandin D2 (PGD2)
which are thought to account for the majority of allergen-
induced bronchoconstriction in allergic asthmatics. Theophyl-
line has been shown to reduce antigen and anti-IgE receptor 
antibody-stimulated histamine release from rat peritoneal mast
cells10 and reduce histamine release from human basophils.11 
However, such effects are only seen at concentrations in excess
of those achievable in vivo. Cultured murine mast cells contain 
a type IV PDE isoenzyme and selective inhibitors of the type IV
isoenzyme have also been shown to inhibit histamine release.6
Effects on lymphocytes
There is evidence to suggest that activated T cells play a key role 
in the pathogenesis of allergic inflammatory diseases such as
bronchial asthma.12 T cells are likely to play a role in all antigen-
driven inflammatory responses since they are the only cell type
that directly recognizes and responds to processed antigens. 
They are involved in many stages of the allergic response
including regulation of IgE production by B cells and recruit-
ment of other inflammatory cells such as eosinophils. In the mid
1970s, theophylline was used to produce clones of peripheral 
blood mononuclear cells with possible suppressor cell activity.13
In a more recent study, incubation of peripheral blood lympho-
cytes with theophylline caused them to suppress autologous cell
responses.14 This phenomenon was demonstrated to be due to 
a subgroup of T cells which were sensitive to in vitro stimulation 
by theophylline.13 Subsequently a number of in vitro investiga-
tions have suggested that xanthines have the ability to modify 
lymphocyte behaviour, in particular the ability to inhibit the lym-
phocyte proliferation.15 Two studies reported that theophylline
inhibited T cell proliferation following antigenic16 and mito-
genic17 stimulation and it has also been shown to diminish E 
rosette formation.18 The synthesis and release of interleukin 2
(IL-2) is a necessary stimulus for lymphocyte proliferation.19 It is 
of interest therefore that theophylline has been found to inhibit 
interferon-gamma (IFN-gamma)-induced expression of IL-2
receptors on a cultured lymphocyte line.20 Theophylline can also 
inhibit production16 and release2' of IL-2.
 Type III and IV PDE isoenzymes have been characterized in T 
cells22,23 and selective inhibitors of the type III and IV PDE iso-
enzyme have been shown to inhibit phytohaemagglutinin (PHA)-
stimulated human24 and murine25 T cell proliferation. In a study 
using rat thymocyte cells, type III, IV and V inhibitors were exam-
ined for their ability to inhibit the concavaline A-stimulated pro-
liferative response.26 The type IV PDE inhibitor, rolipram, was the 
most effective at inhibiting proliferation whilst the type III and V 
inhibitors only modestly inhibited at high concentrations. In
another study, selective inhibitors of the type IV PDE isoenzyme 
inhibited anti-CD3-stimulated human lymphocyte prolifera-
tion15 and combined addition of the type III inhibitor, motapi-
zone, and the type IV inhibitor, rolipram, produced a more 
potent and complete inhibition, an effect which was also seen
with the mixed type III-IV inhibitor, zardaverine. Another, very 
recent study has found that the proliferation and cytokine secre-
tion of T helper (CD4+) and T suppressor (CD8+) cells is inhib-
ited by type III and IV PDE isoenzyme-selective inhibitors.27 There 
is also preliminary evidence to suggest that type IV PDE 
inhibitors can inhibit expression of IL-4 and IL-5 genes in The 
cells.28
 Many studies have examined the effects of selective PDE 
inhibitors on mononuclear cell preparations. Type IV PDE 
inhibitors were shown to inhibit N-formyl-met-leu-phe (fMLP)-
stimulated arachidonic acid29 and tumour necrosis factor-a
(TNF-α)30 release from human mononuclearcells. Type IV and
mixed type III-IV PDE inhibitors have also been demonstrated to
inhibit the PHA-stimulated proliferation of human peripheral 
blood mononuclear cells (HPBM).24,31 In a recent study, the 
atopic PDE IV isoenzyme in mononuclear leukocytes was found
to be more sensitive to type IV inhibitors than the type IV iso-
enzyme from normal subjects32 and the type IV inhibitor, RO 20-
1724, reduced hyper-IgE synthesis by atopic dermatitis cells in
vitro.33 Two studies have also demonstrated that therapeutic lev-
els of theophylline(10-20μg/mL)can inhibit the tumoricidal
activity of natural killer cells.34,35
Effects on macrophages
Airway macrophages arise from circulating monocytes, which 
mature into macrophages during their residence in the airways. 
In asthmatic subjects, macrophages release a variety of chemi-
cal mediators in response to allergen challenge including
potent eosinophil chemoattractants like platelet activating fac-
tor (PAF), leukotriene B4 (LTB4) and cytokines. Studies have 
demonstrated that after exposure to low therapeutic levels of
theophylline, peripheral blood mononuclear cells and alveolar 
macrophages obtained from bronchoalveolar lavage fluid 
(BALF) of normal subjects secrete less superoxide anions in
vitro36 and theophylline has been shown to inhibit opsonized 
zymosan-stimulated H2O2 generation from human alveolar 
macrophages.37 In addition, theophylline and IBMX inhibit the
generation of the potent eosinophil chemoattractants, PAF, 
complement C2 and LTB4 from human monocytes,38,39 and also
the synthesis and release ofTNFafrom human peripheral blood
monocytes.40
 The type IV isoenzyme is the main cAMP PDE isoenzyme that 
has been identified in murine macrophages.41 The selective type 
III PDE inhibitor, motapizone, the type IV inhibitor, rolipram, and
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the mixed type III-IV PDE inhibitor, zardaverine, have been 
shown to inhibit TNF release from human macrophages.15 In 
guinea pig and mouse peritoneal macrophages, PDE IV inhibi-
tion suppresses lipopolysaccharide (LPS)-stimulated TNF pro-
duction42 and superoxide generation.43
Effects on eosinophils
There is now strong evidence to suggest that eosinophils play an 
important role in lung inflammation caused by asthma through 
their ability to release a variety of toxic and proinflammatory 
mediators. These include eicosanoids, reactive oxygen species,
cytokines and basic proteins. The basic proteins, major basic 
protein (MBP), eosinophil cationic protein (ECP) and eosinophil-
derived neurotoxin (EDN) are thought to contribute to the dam-
age observed in the epithelial lining of the airways of 
asthmatics.44,45 Therapeutic concentrations of theophylline and 
other CAMP elevating agents (e. g. CAMP analogues) have been 
demonstrated to inhibit the release of basic proteins such as
EDN46 and also immunoglobulin-induced eosinophil degranu-
lation. In another study, theophylline was found to inhibit the 
release of ECP and reactive oxygen species from highly purified 
blood eosinophils47 with a potency nearly identical to that for
inhibition of PDE type IV activity. Superoxide anions and arachi-
donic acid derivatives are generated by leukocytes and it has 
been suggested that they may contribute to airway injury, 
oedema and smooth muscle contraction seen in asthma.48 In
one study by Yukawa et al., concentrations of theophylline 
which cover the therapeutic range (10-6-10-5 mmol), signifi-
cantly potentiated opsonized zymosan-induced O2 generation 
from isolated guinea pig and human eosinophils, whereas at
high concentrations there was a significant inhibition of the 
release.49 In another study, therapeutic concentrations of theo-
phylline(10-50μmol) have been shown to significantly inhibit
the respiratory burst and also arachidonic acid metabolite gen-
eration induced by chemotactic peptides such as fMLP and the 
calcium ionophore, A23187.50,51
 The type IV PDE isoenzyme is the only PDE isoenzyme which 
has been characterized in guinea pig eosinophils52 and a num-
ber of studies have examined the effect of isoenzyme selective 
inhibitors on the respiratory burst and the release of cationic
proteins from guinea pig eosinophils. The type IV PDE inhibitors, 
rolipram and RO 20-1724, at concentrations which inhibited 
degradation of CAMP have also been found to inhibit the leuko-
cyte respiratory burst in both activated guinea pig peritoneal 
and human eosinophils.52-55 Another selective type IV PDE
inhibitor, RP 73401, inhibited superoxide generation as well as 
LTB4-stimulated MBP and ECP release from guinea pig eosin-
ophils, however, these were dose dependent.56
Effects on neutrophils
Neutrophils, like eosinophils, have the potential to damage the 
airways and exacerbate the inflammatory process through their
ability to release reactive oxygen species, cationic proteins and 
lipid inflammatory mediators. Incubation of neutrophils with
theophylline concentrations which cover the therapeutic range 
inhibited LTB4 generation by 90%. In three studies by Nielson et 
al., therapeutic concentrations of theophylline inhibited neu-
trophil activation and potentiated the effect of isoprenaline.50-53 
In contrast, two separate studies have reported an enhancing 
effect of therapeutic concentrations of theophylline on human
neutrophil superoxide production.57-59 The reason for these dis-
crepancies is not yet known. Like eosinophils, the type IV iso-
enzyme has been characterized in neutrophils. Rolipram and 
RO 20-1724 can inhibit the respiratory burst in neutrophils,53
an effect that can be inhibited by the protein kinase A antago-
ist, H89.59 Inhibition of PDE isoenzymes by selective inhibitors 
has also been shown to decrease the chemotaxis and chemoki-
nesis of human blood neutrophils in vitro.60
Effects on endothelial and epithelial cells
The endothelium provides the major permeability barrier of the 
vessel wall. Polymorphonuclear leukocytes may damage
endothelial cells by releasing agents, such as H2O2, resulting in 
an increase in vascular permeability. There is evidence to sug-
gest that type III and IV PDE inhibitors abolish the increase in
permeability of cultured porcine endothelial cells induced by 
H2O2, suggesting that PDE inhibition may result in a decrease in 
microvascular permeability.61
 Epith lial cells not only act as a protective barrier to the external 
environment but also represent a metabolically active secreting tis-
sue which may actively interact with inflammatory cells. Human air-
way epithelial cells produce PAF, granulocyte macrophage colony 
stimulating factor (GM-CSF), prostaglandin E2 (PGE2), PGF2a and
15-lipoxygenase pathway-derived eicosanoids, all of which may 
influence other inflammatory cell types. IBMX, a non-selective PDE 
inhibitor has been found to inhibit the bradykinin-stimulated gener-
ation of PGE2 by epithelial cells.62
IN VIVO STUDIES
The 'anti-inflammatory' properties of theophylline and selective 
PDE inhibitors has been examined in a number of studies utiliz-
ing different animal models. Exposure of sensitized animals to
antigen results in acute airway obstruction and an influx of 
inflammatory cells into the airway lumen. These animal models 
have been used to examine the effect of both currently pre-
scribed anti-asthma drugs and also novel anti-asthma agents. 
In rat8,63 and guinea pig models,64 xanthines have been shown 
to inhibit the inflammatory and hyper-responsive components
induced by allergen. Xanthines have also been shown to attenu-
ate the late response65 and the eosinophil-infiltration induced by 
allergen66 in allergic rabbits.
 Acute administration of theophylline and isbufylline has been 
reported to reduce eosinophil infiltration induced by allergen
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challenge in actively sensitized guinea pigs.64,67 A number of 
studies have also demonstrated that acute administration of 
type IV and mixed type III-IV PDE inhibitors is effective at inhibit-
ing eosinophil recruitment into the lungs of sensitized guinea 
pigs. The type IV PDE inhibitor, rolipram,68 and the mixed type
III-IV PDE inhibitor, zardaverine,69 given before antigen chal-
lenge have also been found to inhibit eosinophil accumulation 
in the airways. In a separate study, prior administration of the 
mixed type III-IV inhibitor, benzafentrine, prevented eosinophil
accumulation in pulmonary airways of guinea pigs70 induced by
human recombinant GM CSF,IL-3 and mouse TNFα.
Theophylline and the type IV inhibitors, rolipram and RO 20-
1724, significantly reduced antigen and PAF-induced 
eosinophil recruitment.71 RP 73401 inhibited antigen induced
bronchospasm and eosinophil recruitment in previously sensi-
tized conscious guinea pigs.72 In a study by Turner et al., 
rolipram given 1h before antigen challenge inhibited both 
eosinophil recruitment and the development of airway hyper-
responsiveness in allergic monkeys.3
 However, most studies which have examined the effect of 
theophylline and selective PDE isoenzyme inhibitors on 
eosinophil accumulation are not directly relevant to the clinical 
use of theophylline for two reasons; firstly the doses which have 
been used in these studies have been given as one acute dose,
before antigen challenge, and secondly because the doses used 
in these studies are often much higher than those used clinically. 
Two studies conducted by Sanjar et al. found that 7-day admin-
istration of either theophylline or the mixed type III-IV PDE
inhibitor, benzafentrine, inhibited both PAF74 and allergen-
induced75 pulmonary eosinophil accumulation in guinea pig at 
doses equivalent to those used clinically. Furthermore we have 
recently shown that much lower concentrations of the mixed
PDE type III-IV inhibitor, zardaverine, are required to inhibit 
eosinophil infiltration when the drug is administered chronically 
compared with when the drug is administered acutely.76 In addi-
tion, rolipram given twice daily for 3 days before antigen chal-
lenge attenuated antigen-induced airway hyper-responsiveness 
and pulmonary eosinophilia in the allergic rabbit.66 The type IV 
inhibitor, rolipram, has also been shown to prevent recruitment 
of eosinophils to the skin.77
 Microvascular leakage in asthmatic airways leads to plasma 
exudation into the airway lumen and plasma exudation is a con-
sistent indicator of airway inflammation.77 Theophylline has 
been demonstrated to reduce plasma exudation in the guinea 
pig tracheobronchial mucosa induced by local administration 
of inflammatory stimuli.79-82 In a separate study, theophylline
and rolipram inhibited PAF-induced leakage into bronchial 
walls as well as into BALF.83 A PDE type IV inhibitor has also 
been shown to be effective at inhibiting airway microvascular 
leakage induced by PAF and allergen in guinea pigs.84
Clinical studies
Plasma exudation is a consistent indicator of ongoing inflam-
matory processes in both asthma and allergic rhinitis, and is 
used as a clinical model of airway inflammation to study the 
effects of anti-asthma agents. Treating patients with allergic
rhinitis with theophylline has been demonstrated to reduce nasal 
plasma exudate secretion.7,85 Several studies have reported that 
theophylline has a minimal effect on acute allergic bronchocon-
striction which suggests that theophylline is not likely to inhibit
lung mast cells in vivo in any major way.9,86 This conclusion is sup-
ported by a recent study showing that treatment with theophylline 
for 5 weeks did not alter the increased levels of the mast-cell-
derived mediators, PGD2 and histamine, in BAL fluid.87
 However, in another study, a 1 week course of theophylline 
treatment caused a reduction in histamine release in subjects 
with allergic rhinitis following antigen challenge.85 A reduction 
in the early response to allergen in the skin during treatment with
theophylline with no change in the response of the skin to 
injected histamine was also found, suggesting that theophylline 
may be affecting endogenous histamine release.
 A number of studies have examined the effect of chronic 
treatment with theophylline on the behaviour and number of dif-
ferent inflammatory cell types found in human blood or BALF. In 
one study, after asthmatic children were treated for 10 days with
oral theophylline, a reduction in neutrophil and mononuclear 
cell chemotaxis was observed.88 Alveolar macrophages have 
been shown to generate less superoxide ex vivo after in vivo oral
theophylline treatment. A reduction in alveolar macrophage 
intracellular killing, bactericidal killing and H2O2 release was 
also observed, and the degree of impairment was found to cor-
relate well with BAL theophylline concentrations.89 In a separate 
study, the effect of theophylline on eosinophil and neutrophil 
activity was compared with that of budesonide in a 1 year
double blind trial. Both drugs had similar effects in reducing 
eosinophil and neutrophil activation as well as having compa-
rable clinical efficacy.90
 The late asthmatic reaction (LAR) to allergen exposure has 
commonly been used as a model of airway inflammation and 
this model has been used to evaluate anti-inflammatory drugs.
Several studies have now reported that theophylline can inhibit 
the LAR.86,91,92 Interestingly, if allergic subjects are challenged 
with antigen after a period of chronic treatment with theo-
phylline, an inhibition of the LAR at subbronchodilator plasma
concentrations occurs.91,93 Similar results have been found dur-
ing oral theophylline therapy after challenge with toluene di-iso-
cyanate in sensitive asthmatics.94 Theophylline has also been 
reported to reduce the overnight fall in forced expiratory volume
in 1s (FEV)1 and also attenuated the bronchoalveolar lavage 
(BAL) neutrophil accumulation observed in patients with noctur-
nal asthma.95
 There is evidence from two separate studies on asthmatic 
children that a decrease in the number of peripheral blood T
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cells which express suppressor activity occurs96,97 and one of 
these studies found a correlation between T suppressor cell 
numbers and asthma severity. In both studies, after 1 month of 
theophylline treatment, the number of T suppressor cells
returned to the normal level of the control group. In another 
study, chronic treatment with theophylline resulted in an 
increase in the number and activity of T suppressor cells found 
in asthmatic subjects.98 Asthmatics who are on long-term theo-
phylline treatment have more peripheral T cells that are able to 
suppress plaque formation in lymphocyte cultures and have a 
reduced in vitro graft versus host response than do asthmatics 
who are on other treatments.14 In a study performed by Fink et 
al., asthmatics were chronically treated with theophylline.
Theophylline therapy was then withdrawn and clinical, func-
tional and immunological parameters were studied. A clinical 
deterioration and fall in lung function was seen together with a 
fall in activated T helper (CD4+) and T suppressor (CD8+)
peripheral blood lymphocytes.99 Bronchial biopsies which were 
performed in a subgroup of patients showed an increase in the 
number of CD4+ and CD8+ T cells during theophylline with-
drawal suggesting that theophylline may inhibit T cell trafficking
from the circulation into the airways.100 In this study the mean 
plasma theophylline concentration was<10mg/L demonstrat-
ing that modulatory effects may be observed at low plasma con-
centrations. In a study by Ward et al., theophylline at a serum
concentration of 7.8mg/L inhibited the late asthmatic reaction 
following allergen challenge and suppressed the allergen-
induced increase in CD4+ and CD8+ lymphocytes in peripheral 
blood,9 48h after allergen challenge.
 Finally, a recent study has shown that treatment of mild aller-
gic subjects with theophylline for 6 weeks significantly reduced 
the number of EG2+ eosinophils in biopsies obtained from 
allergic subjects and the number of CD4+ lymphocytes in
BALF.87,93 These effects occurred with plasma levels of 6.7mg/L 
which are considered subbronchodilator and suggest that the 
anti-inflammatory and immunomodulatory actions of theo-
phylline may occur at lower concentrations than those sug-
gested to induce bronchodilatation.93 These findings have 
recently been confirmed by measuring EG2+ eosinophils in BAL 
fluid/sputum in patients undergoing bronchial pnovation.101 
Such findings may have significant implications on the future
use of xanthines and selective PDE isoenzyme inhibitors as toxi-
city appears unimportant at lower plasma levels. Furthermore, 
these findings suggest that theophylline should be considered as 
having important anti-inflammatory actions in the lung and 
should be re-evaluated in the treatment of asthma.
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